TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21190800

Group type: EXPERIMENTAL
Intervention: Melatonin treatment (single implants on two occasions in summer, n=1399)
Number of subjects: 3901

Group type: EXPERIMENTAL
Intervention: Melatonin treatment (n=1399)
Number of subjects: 3901

Group type: EXPERIMENTAL
Intervention: Melatonin treatment in Herd A (n=1399)
Number of subjects: 3901

Group type: EXPERIMENTAL
Intervention: Melatonin treatment at 60kg live-weight in Year 1
Number of subjects: 3901

Group type: COMPARATOR
Intervention: Control group (untreated, n=2502)
Number of subjects: 3901

Group type: EXPERIMENTAL
Intervention: Melatonin treatment in Herd B (n=1399)
Number of subjects: 3901
Study: 19843776

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 75
Study: 18075942

Group type: EXPERIMENTAL
Intervention: VR + CM (Vocational Rehabilitation + Contingency Management)
Number of subjects: 100

Group type: COMPARATOR
Intervention: VR only (Vocational Rehabilitation only)
Number of subjects: 100
Study: 14754784

Group type: EXPERIMENTAL
Intervention: Continuous sertraline (50-100 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent sertraline (50-100 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11553257

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg with metoclopramide 5 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg intravenously
Number of subjects: 120
Study: 9631220

Group type: EXPERIMENTAL
Intervention: Dynamic high resolution ultrasound technique for presence of posterior wall deficiency
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dynamic high resolution ultrasound technique
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Surgical, clinical, and ultrasound follow up for players who underwent hernia repair
Number of subjects: 35
Study: 7946181

Group type: EXPERIMENTAL
Intervention: Isradipine monotherapy (4.55 +/- 0.56 mg twice daily)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Isradipine plus bopindolol (7.5 +/- 0.63 mg twice daily and 1.16 +/- 0.12 mg once daily)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Isradipine monotherapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Isradipine plus bopindolol
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Isradipine monotherapy and Isradipine plus bopindolol
Number of subjects: 41
Study: 3041824

Group type: EXPERIMENTAL
Intervention: Once-daily evening doses of controlled-release theophylline (Uniphyl tablets)
Number of subjects: 300
Study: 7433519

Group type: EXPERIMENTAL
Intervention: Mianserin 30-80 mg daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diazepam 15-40 mg daily
Number of subjects: 80
Study: 30265333

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.2 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 150
Study: 28667408

Group type: EXPERIMENTAL
Intervention: Daily administration of S-1 at a standard dose of 80 mg/m2/day
Number of subjects: 132

Group type: COMPARATOR
Intervention: Alternate-day administration of S-1 on 4 days a week
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Daily administration of S-1
Number of subjects: 132

Group type: COMPARATOR
Intervention: Alternate-day administration of S-1
Number of subjects: 132
Study: 26081934

Group type: EXPERIMENTAL
Intervention: 16-week exercise intervention (3 sessions/week)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (control) group
Number of subjects: 150
Study: 23108008

Group type: EXPERIMENTAL
Intervention: Complete Revitalens MPDS
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Biotrue MPDS
Number of subjects: 25
Study: 20825804

Group type: EXPERIMENTAL
Intervention: Intraosseous (IO) line placement by first responders wearing PPE
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intraosseous (IO) line placement by first receivers wearing PPE
Number of subjects: 18

Group type: COMPARATOR
Intervention: Overall comparison of time to completion among PPE levels
Number of subjects: 18

Group type: COMPARATOR
Intervention: Line placements
Number of subjects: 18
Study: 19954052

Group type: COMPARATOR
Intervention: MELD score < or = 9
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: MELD score 10-19
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: MELD score 20-29
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: MELD score > or = 30
Number of subjects: 254

Group type: COMPARATOR
Intervention: MELD score < or = 19
Number of subjects: 254
Study: 17508038

Group type: EXPERIMENTAL
Intervention: Neuroprotective drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 15600246

Group type: EXPERIMENTAL
Intervention: Peru-15 (recombinant cholera vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase II trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase III trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase IIb and phase III challenge studies
Number of subjects: 0
Study: 11380056

Group type: EXPERIMENTAL
Intervention: Whole-school intervention including establishment of a school-based adolescent health team and implementation of strategies based on student surveys.
Number of subjects: 26
Study: 9582768

Group type: EXPERIMENTAL
Intervention: Information leaflet (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Leaflet and verbal explanation (Group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Verbal explanation only (Group C)
Number of subjects: 120
Study: 8109763

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg/kg (maximum = 8 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60
Study: 3396118

Group type: EXPERIMENTAL
Intervention: Fosfomycin 8 g b.i.d.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ampicillin 2 g t.i.d.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 38
Study: 5781487

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (40 to 80 mg daily for 17 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (40 to 80 mg daily for 9 months)
Number of subjects: 0
Study: 30650159

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) sign-reading assistant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no AR assistance)
Number of subjects: 0
Study: 29162078

Group type: EXPERIMENTAL
Intervention: ProPA program (physical activity oriented home rehabilitation program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study: 26391359

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 100U
Number of subjects: 1105

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1105
Study: 22804755

Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg/day for 28 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study: 21709648

Group type: EXPERIMENTAL
Intervention: Modified triple loop corrector (appliance therapy)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Positive reinforcement (reward therapy)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 18651343

Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg b.i.d. for 7 days followed by 75 mg b.i.d. for another 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 12
Study: 17961403

Group type: EXPERIMENTAL
Intervention: Fixed dosage of ICS (fluticasone) plus LABA (salmeterol) maintained for 18 months in group A
Number of subjects: 65

Group type: COMPARATOR
Intervention: Tailored dosage or withdrawal of therapy according to clinical control in group B
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Step-down or withdrawal according to PC(35) sGaw in group C
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Combined therapy with ICS plus LABA
Number of subjects: 65

Group type: COMPARATOR
Intervention: Adjustment of therapy based on clinical parameters in group B
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PC(35) sGaw monitoring in therapy adjustment
Number of subjects: 65
Study: 15336593

Group type: EXPERIMENTAL
Intervention: HRT group (n = 146) received a sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate and calcium lactate, 500 mg/day (equal to 93 mg Ca2+) alone or in combination with vitamin D3, 100‐300 IU/day.
Number of subjects: 316

Group type: COMPARATOR
Intervention: non-HRT group (n = 170) received calcium lactate, 500 mg alone or in combination with vitamin D3, 100‐300 IU/day.
Number of subjects: 316

Group type: COMPARATOR
Intervention: non-HRT group (n = 170) with wild-type NPY polymorphism.
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: HRT group (n = 146) with Leu7/Pro7 genotype.
Number of subjects: 316
Study: 12964222

Group type: EXPERIMENTAL
Intervention: Profiling bed with a pressure-reducing foam mattress
Number of subjects: 100

Group type: COMPARATOR
Intervention: Flat-based bed with an appropriate pressure-redistributing mattress
Number of subjects: 100
Study: 9621829

Group type: EXPERIMENTAL
Intervention: Successive recognition judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ease judgments
Number of subjects: 0
Study: 7624633

Group type: EXPERIMENTAL
Intervention: Transcortical through the middle T2 gyrus
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Translyvian through the deep sylvian fissure
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Transcortical subpial through the anterior T1 gyrus
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Transcortical through the first temporal sulcus
Number of subjects: 80
Study: 2455148

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine tablet
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2 X 10 mg nifedipine capsules
Number of subjects: 6
Study: 31920097

Group type: EXPERIMENTAL
Intervention: semi-immersive virtual reality training (sVRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: conventional cognitive training (Control Group)
Number of subjects: 60
Study: 31787023

Group type: EXPERIMENTAL
Intervention: Linear Periodized Training (LP)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Non-Linear Periodized Training (NLP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 39
Study: 30340637

Group type: EXPERIMENTAL
Intervention: Video clinic appointments
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard face-to-face appointments
Number of subjects: 180
Study: 28739794

Group type: EXPERIMENTAL
Intervention: AZD-5847 (500 mg once daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AZD-5847 (1,200 mg once daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AZD-5847 (500 mg twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AZD-5847 (800 mg twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AZD-5847
Number of subjects: 60

Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sutezolid
Number of subjects: 60
Study: 26276704

Group type: EXPERIMENTAL
Intervention: Intensive Parental Coaching (IPC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard Family-Based Treatment (FBT)
Number of subjects: 45
Study: 23695207

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet with weekly group support and work cafeteria options for 18 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: No diet changes for 18 weeks
Number of subjects: 100
Study: 21145112

Group type: EXPERIMENTAL
Intervention: Guided self-help (Problem Solving Treatment and exposure) for 6 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 120
Study: 18804343

Group type: EXPERIMENTAL
Intervention: Tooth section technique used
Number of subjects: 25

Group type: COMPARATOR
Intervention: No tooth section technique used (Control)
Number of subjects: 25
Study: 17075089

Group type: EXPERIMENTAL
Intervention: Closing wedge technique
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Opening wedge technique
Number of subjects: 92

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 92
Study: 12667723

Group type: EXPERIMENTAL
Intervention: apomorphine SL
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 10889113

Group type: EXPERIMENTAL
Intervention: Radiation therapy (14.4 Gy, 1.8 Gy per day, five fractions per week)
Number of subjects: 40
Study: 8769361

Group type: EXPERIMENTAL
Intervention: DHEA 40 mg sublingually twice daily for 8 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1555628

Group type: EXPERIMENTAL
Intervention: i.v. infusion of 1.5 MU of streptokinase
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 4002782

Group type: EXPERIMENTAL
Intervention: 30 mg muzolimine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide/50 mg triamterene
Number of subjects: 2
Study: 30065082

Group type: EXPERIMENTAL
Intervention: Gas mask
Number of subjects: 14

Group type: COMPARATOR
Intervention: No gas mask
Number of subjects: 14
Study: 27797291

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with everolimus-eluting stents
Number of subjects: 1905

Group type: COMPARATOR
Intervention: Coronary-artery bypass grafting (CABG)
Number of subjects: 1905
Study: 24876771

Group type: EXPERIMENTAL
Intervention: CDSMP plus supervised exercise
Number of subjects: 84

Group type: COMPARATOR
Intervention: CDSMP alone (control)
Number of subjects: 84
Study: 22051247

Group type: EXPERIMENTAL
Intervention: Allevyn™ (polyurethane dressing)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Kaltostat® (calcium alginate dressing)
Number of subjects: 36
Study: 20204944

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal (COG) writing
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Emotional disclosure (ED)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Combination of emotional disclosure and cognitive reappraisal (ED and COG)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 130
Study: 18831745

Group type: EXPERIMENTAL
Intervention: OAK program (education self-management program for OA of the knee)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard medical management (control group)
Number of subjects: 146
Study: 16444855

Group type: EXPERIMENTAL
Intervention: 3 g of L-arginine daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0 g of L-arginine daily (Control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 6 g of L-arginine daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 9 g of L-arginine daily
Number of subjects: 80
Study: 12131067

Group type: EXPERIMENTAL
Intervention: Exposure in vivo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Graded activity
Number of subjects: 6
Study: 10534332

Group type: EXPERIMENTAL
Intervention: High-quality trials investigating portal hypertension
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: High-quality trials that are multicentered
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: High-quality trials sponsored by public organizations
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: High-quality trials sponsored by the drug and device industry
Number of subjects: 235
Study: 7494013

Group type: EXPERIMENTAL
Intervention: FAN anaerobic bottles
Number of subjects: 694

Group type: COMPARATOR
Intervention: Standard anaerobic bottles
Number of subjects: 694
Study: 1955631

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 1

Group type: COMPARATOR
Intervention: Brazil ginseng dust exposure
Number of subjects: 1

Group type: COMPARATOR
Intervention: Korean ginseng (Panax ginseng)
Number of subjects: 1
Study: 6961468

Group type: EXPERIMENTAL
Intervention: gamma-linolenic acid in the form of evening primrose oil (Efamol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study: 30657996

Group type: EXPERIMENTAL
Intervention: CL-108 (Hydrocodone 7.5 mg/Acetaminophen 325 mg/Rapid-Release, Low-Dose Promethazine 12.5 mg)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: CL-108
Number of subjects: 466

Group type: COMPARATOR
Intervention: Hydrocodone 7.5 mg/Acetaminophen 325 mg (HC/APAP)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study: 30400898

Group type: EXPERIMENTAL
Intervention: Self-testing (oral testing)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Provider administered test (finger-prick testing)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Provider administered test (in-person counselling)
Number of subjects: 150
Study: 27085261

Group type: EXPERIMENTAL
Intervention: Educational web page
Number of subjects: 96

Group type: COMPARATOR
Intervention: Wait 30 minutes (Control)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Treatment-experienced cohort
Number of subjects: 96
Study: 25198108

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 36
Study: 22225858

Group type: EXPERIMENTAL
Intervention: Rivaroxaban with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivaroxaban with concomitant use of platelet function inhibitors/acetylsalicylic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin with concomitant use of platelet function inhibitors/acetylsalicylic acid
Number of subjects: 0
Study: 20361031

Group type: EXPERIMENTAL
Intervention: Albendazole therapy
Number of subjects: 1541
Study: 17924895

Group type: EXPERIMENTAL
Intervention: Biovalve PUR cannula
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vialon cannula
Number of subjects: 70
Study: 15834592

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg with 1,000 mg calcium and 800 IU vitamin D daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1,000 mg calcium and 800 IU vitamin D daily
Number of subjects: 120
Study: 11902616

Group type: EXPERIMENTAL
Intervention: Endorsement of individual mobility ideology by low-status group members
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Endorsement of individual mobility ideology by high-status group members
Number of subjects: 3
Study: 10089855

Group type: EXPERIMENTAL
Intervention: Pacing therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: No pacing
Number of subjects: 42
Study: 8574724

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clonidine (0.150 mg)
Number of subjects: 16
Study: 2297502

Group type: EXPERIMENTAL
Intervention: DNCB applied to an area of less than 1 cm2
Number of subjects: 0

Group type: COMPARATOR
Intervention: DNCB applied to larger areas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing the concentration of DNCB while keeping the area constant
Number of subjects: 0
Study: 876327

Group type: EXPERIMENTAL
Intervention: Early systemic chemotherapy (5‐fluorouracil, cyclophosphamide and prednisone)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Delayed treatment upon appearance of progressive metastatic disease
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Early treatment group (excluding early progression)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (excluding early progression)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Immediate treatment group
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Early progression group
Number of subjects: 75
Study: 31402735

Group type: EXPERIMENTAL
Intervention: PPROM
Number of subjects: 1729

Group type: COMPARATOR
Intervention: sPTL
Number of subjects: 1729
Study: 31082947

Group type: EXPERIMENTAL
Intervention: 20-gauge fenestrated IV catheter (group 2)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 22-gauge fenestrated IV catheter (group 3)
Number of subjects: 300

Group type: COMPARATOR
Intervention: 20-gauge nonfenestrated conventional IV catheter (group 1)
Number of subjects: 300
Study: 28587203

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (520 mg of DHA + EPA-enriched fish-oil daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 54
Study: 26158889

Group type: EXPERIMENTAL
Intervention: Guided Internet Therapy (IT)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Group Therapy (GT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 116
Study: 24479211

Group type: EXPERIMENTAL
Intervention: 7% maleic acid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite followed by 7% maleic acid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite followed by 17% EDTA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 21647905

Group type: EXPERIMENTAL
Intervention: PlasmaKnife tonsillectomy (PKT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Monopolar cautery tonsillectomy (MCT)
Number of subjects: 32
Study: 19602503

Group type: EXPERIMENTAL
Intervention: 24 h on-call duty (OCD)
Number of subjects: 30
Study: 16482367

Group type: EXPERIMENTAL
Intervention: Risk Index Score (RISc) algorithm
Number of subjects: 2576

Group type: EXPERIMENTAL
Intervention: Statistical validation of RISc
Number of subjects: 2576
Study: 14629081

Group type: EXPERIMENTAL
Intervention: Patient-centered interdisciplinary team intervention designed to improve transitions across sites of geriatric care
Number of subjects: 0
Study: 11898712

Group type: EXPERIMENTAL
Intervention: Therapeutic interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional methodologies
Number of subjects: 0
Study: 9699418

Group type: EXPERIMENTAL
Intervention: MND ANA immunofluorescence pattern
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Affinity purified anti-70 kDa
Number of subjects: 21
Study: 8018456

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dopamine infusion (3 micrograms kg‐1 min‐1) with placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dopamine infusion (3 micrograms kg‐1 min‐1) with metoprolol
Number of subjects: 8